Fig. 11.

Coronary venous Po₂ vs. myocardial oxygen consumption at rest and during exercise in the absence and presence of the Kv channel blocker 4-aminopyridine [4-AP; data from Berwick et al. (10); A] and the K_ATP channel inhibitor glibenclamide [data from Duncker et al. (35); B].